Search

Your search keyword '"Graupner, Vilma"' showing total 11 results
Start Over Author "Graupner, Vilma"
11 results on '"Graupner, Vilma"'

1. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.

Author

Neal, Joel, Pavlakis, Nick, Kim, Sang-We, Goto, Yasushi, Lim, Sun Min, Mountzios, Giannis, Fountzilas, Elena, Mochalova, Anastasia, Christoph, Daniel C., Bearz, Alessandra, Quantin, Xavier, Palmero, Ramon, Antic, Vladan, Chun, Elaine, Edubilli, Tirupathi Rao, Lin, Ya-Chen, Huseni, Mahrukh, Ballinger, Marcus, Graupner, Vilma, and Curran, Dominic

Published
2024
Full Text
View/download PDF

2. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Author

Jotte, Robert, Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodríguez-Abreu, Delvys, Hussein, Maen, Soo, Ross, Conter, Henry J., Kozuki, Toshiyuki, Huang, Kuan-Chieh, Graupner, Vilma, Sun, Shawn W., Hoang, Tien, Jessop, Helen, McCleland, Mark, Ballinger, Marcus, Sandler, Alan, and Socinski, Mark A.

Published
2020
Full Text
View/download PDF

3. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation

Author

Liu, Stephanie N., primary, Marchand, Mathilde, additional, Liu, Xiaoyan, additional, Ingle, Gladys, additional, Maiya, Vidya, additional, Graupner, Vilma, additional, Elze, Markus C., additional, Chan, Phyllis, additional, Hsu, Joy C., additional, Lin, Alyse, additional, Vadhavkar, Shweta, additional, Wu, Benjamin, additional, and Bruno, Rene, additional

Published
2022
Full Text
View/download PDF

4. Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

Author

Huober, Jens, Barrios, Carlos H., Niikura, Naoki, Jarząb, Michał, Chang, Yuan-Ching, Huggins-Puhalla, Shannon L., Pedrini, José, Zhukova, Lyudmila, Graupner, Vilma, Eiger, Daniel, Henschel, Volkmar, Gochitashvili, Nino, Lambertini, Chiara, Restuccia, Eleonora, and Zhang, Hong

Published
2022
Full Text
View/download PDF

6. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Author

Jotte, Robert M., primary, Cappuzzo, Federico, additional, Vynnychenko, Ihor, additional, Stroyakovskiy, Daniil, additional, Rodriguez Abreu, Delvys, additional, Hussein, Maen A., additional, Soo, Ross A., additional, Conter, Henry Jacob, additional, Kozuki, Toshiyuki, additional, Silva, Carlos, additional, Graupner, Vilma, additional, Sun, Shawn, additional, Lin, Ray S, additional, Kelsch, Claudia, additional, Kowanetz, Marcin, additional, Hoang, Tien, additional, Sandler, Alan, additional, and Socinski, Mark A., additional

Published
2018
Full Text
View/download PDF

11. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway.

Author

Gillissen B, Essmann F, Graupner V, Stärck L, Radetzki S, Dörken B, Schulze-Osthoff K, and Daniel PT

Subjects
Adenoviridae genetics, Amino Acid Sequence, Apoptosis Regulatory Proteins, Caspases metabolism, Cell Line, Cytochrome c Group metabolism, Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Viral, Humans, Intracellular Membranes metabolism, Membrane Proteins metabolism, Mitochondrial Proteins, Protein Conformation, Protein Isoforms, Proteins chemistry, Proteins genetics, Proto-Oncogene Proteins chemistry, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-bcl-2 chemistry, Proto-Oncogene Proteins c-bcl-2 genetics, Recombinant Proteins metabolism, Tumor Cells, Cultured, bcl-2 Homologous Antagonist-Killer Protein, bcl-2-Associated X Protein, Apoptosis genetics, Apoptosis physiology, Mitochondria metabolism, Proteins metabolism, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-bcl-2 metabolism
Abstract

Nbk/Bik (natural born killer/Bcl-2-interacting killer) is a tissue-specific BH3-only protein whose molecular function is still largely unknown. To investigate the mechanism of Nbk action, we established a single- vector adenoviral system based on the Tet-off conditional expression of Nbk. Upon Nbk expression, only Bax-positive, but not Bax-deficient cells were found to undergo apoptosis. Interestingly, Nbk failed to induce apoptosis in the absence of Bax, even despite expression of the related molecule Bak. Re-expression of Bax restored the sensitivity to Nbk. Similarly, Bax wild-type HCT116 cells were highly susceptible, whereas HCT116 Bax knock-out cells remained resistant to Nbk-induced apoptosis. In Bax-positive cells, Nbk induced a conformational switch in the Bax N-terminus coinciding with cytochrome c release, mitochondrial permeability transition and caspase-9 processing. Immunoprecipitation studies revealed that Nbk interacts with Bcl-x(L) and Bcl-2 but not with Bax. Since, in addition, Nbk did not localize to the mitochondria, our data suggest a model in which Nbk acts as an indirect killer to trigger Bax-dependent apoptosis, whereas Bak is not sufficient to confer sensitivity to Nbk.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results